GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Compugen Ltd (NAS:CGEN) » Definitions » Research & Development

Compugen (Compugen) Research & Development : $34.47 Mil (TTM As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Compugen Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Compugen's Research & Development for the three months ended in Dec. 2023 was $10.93 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was $34.47 Mil.

Compugen Research & Development Historical Data

The historical data trend for Compugen's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compugen Research & Development Chart

Compugen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.82 22.76 28.69 30.65 34.47

Compugen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.33 7.45 7.76 8.34 10.93

Compugen Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $34.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Compugen  (NAS:CGEN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Compugen Research & Development Related Terms

Thank you for viewing the detailed overview of Compugen's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Compugen (Compugen) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Compugen Ltd (NAS:CGEN) » Definitions » Research & Development
Comparable Companies
XTAE:BLRX XTAE:BONS XTAE:EVGN XTAE:GFC-M XTAE:DNA XTAE:CBI XTAE:MTLF XTAE:PPBT XTAE:XTLB XTAE:CANF OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
CGEN:Israel
Address
26 Harokmim Street, Building D, Azrieli Center, Holon, ISR, 5885849
Website
https://www.cgen.com
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.